<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04948203</url>
  </required_header>
  <id_info>
    <org_study_id>IRB21-0400</org_study_id>
    <nct_id>NCT04948203</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis</brief_title>
  <official_title>SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine whether the drug sirolimus reduces the&#xD;
      likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19&#xD;
      pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hospitalized patients with a diagnosis of COVID-19 pneumonia will be referred to the study&#xD;
      team for potential recruitment. Initial screening will take place using the existing medical&#xD;
      record and in collaboration with the treating team. The study consists of 3 randomly assigned&#xD;
      arms of varying dosages of the study drug&#xD;
&#xD;
      All procedures, with the exception of drug dosing and option sample analysis, align with the&#xD;
      subject's standard of care. Prior to initiating study drug, the subject's standard of care&#xD;
      labs, imaging and oxygen requirements will be reviewed.&#xD;
&#xD;
      Sirolimus will be administered as an oral medication. Subjects who are discharged prior to&#xD;
      receiving 14 days of study drug will be provided with enough study drug to finish at home.&#xD;
&#xD;
      On-study evaluation includes measurement of vital signs and laboratory studies before and&#xD;
      after a patient has received sirolimus while inpatient. As part of routine care, subjects&#xD;
      will be seen daily while in the hospital and will be monitored through blood tests for&#xD;
      general health as well as renal function. Vital signs will be monitored daily while in the&#xD;
      hospital, physical exams, assessment of COVID-19, and CT scans or chest x-rays as necessary&#xD;
      for routine care.&#xD;
&#xD;
      Subjects will return to clinic at 12 weeks for routine lab work and imaging as a part of&#xD;
      study follow-up and will be assessed for pulmonary fibrosis at this time.&#xD;
&#xD;
      Additionally, University of Chicago Medicine patients will have the option to allow&#xD;
      investigators to use leftovers from tubes of blood drawn for clinical tests that would&#xD;
      otherwise be discarded. This will apply to any blood collected during that respective&#xD;
      hospital stay as well as up to 1 year after study enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Pulmonary Fibrosis as evidenced by CT scan</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of patients with &gt;10% pulmonary fibrosis on chest CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>10% Threshold for Pulmonary Fibrosis evidenced by CT scan</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of patients with &gt;10% pulmonary fibrosis on chest CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative Fibrotic markers on chest CT</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of patients with the presence or absence of chest CT imaging markers of fibrosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative Fibrosis Score on chest CT</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Quantitative Fibrosis Score on chest CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Increased Supplemental Oxygen from Baseline</measure>
    <time_frame>84 Days</time_frame>
    <description>Number of days over which the participant requires supplemental oxygen in excess over baseline supplemental oxygen requirement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function Test impairment</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of subjects with the presence of abnormal indices of lung function tests</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety - Rate of Liver Function Test abnormalities</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Number of patients in a study arm who develop severe impairment of liver function tests exceeding three times the upper limit of normal</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <condition>COVID-19 Pneumonia</condition>
  <condition>Long COVID</condition>
  <arm_group>
    <arm_group_label>Sirolimus 0.5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will take Sirolimus 0.5mg orally daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus 1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will take Sirolimus 1mg orally daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will take Sirolimus 2mg orally daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Triangular-shaped tablet</description>
    <arm_group_label>Sirolimus 0.5mg</arm_group_label>
    <arm_group_label>Sirolimus 1mg</arm_group_label>
    <arm_group_label>Sirolimus 2mg</arm_group_label>
    <other_name>RAPAMUNE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults ≥ 18 years of age&#xD;
&#xD;
          -  Approval from the patient's primary inpatient service&#xD;
&#xD;
          -  Hospitalized&#xD;
&#xD;
          -  Diagnosed with COVID-19 pneumonia&#xD;
&#xD;
          -  Positive test for active SARS-CoV-2 infection&#xD;
&#xD;
          -  Requiring supplemental oxygen ≥ 5LNC or ≥ 40% FiO2.&#xD;
&#xD;
          -  Chest computed tomography (CT) at admission with &lt; 10% pulmonary fibrosis&#xD;
&#xD;
          -  Ability to provide written informed consent on the part of the subject or, in the&#xD;
             absence of decisional capacity of the subject, an appropriate surrogate (e.g. a&#xD;
             legally authorized representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of previous pulmonary fibrosis or an interstitial lung disease.&#xD;
&#xD;
          -  Clinical features or known diagnosis of malignancy or active non-COVID-19 infection,&#xD;
             including untreated latent tuberculosis.&#xD;
&#xD;
          -  History of unstable or deteriorating cardiac disease (including myocardial infarction,&#xD;
             coronary artery bypass surgery or angioplasty within the past 6 months, congestive&#xD;
             heart failure requiring hospitalization within the past 6 months, or uncontrolled&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Known history of hypersensitivity to sirolimus.&#xD;
&#xD;
          -  History of unstable or deteriorating neurologic disease (including TIAs or stroke).&#xD;
&#xD;
          -  Pregnant or lactating females. Females of child bearing potential are required to have&#xD;
             a negative pregnancy test prior to treatment and practice abstinence or prevent&#xD;
             pregnancy by at least a barrier method of birth control.&#xD;
&#xD;
          -  Investigational therapy for any indication within 28 days prior to treatment.&#xD;
&#xD;
          -  Current treatment with any drugs that are strong inhibitors of CYP3A4.&#xD;
&#xD;
          -  Tofacitinib&#xD;
&#xD;
          -  Clarithromycin&#xD;
&#xD;
          -  Telithromycin&#xD;
&#xD;
          -  Nefazodone&#xD;
&#xD;
          -  Itraconazole&#xD;
&#xD;
          -  Ketoconazole&#xD;
&#xD;
          -  Atazanavir&#xD;
&#xD;
          -  Darunavir&#xD;
&#xD;
          -  Indinavir&#xD;
&#xD;
          -  Lopinavir&#xD;
&#xD;
          -  Nelfinavir&#xD;
&#xD;
          -  Ritonavir&#xD;
&#xD;
          -  Saquinavir&#xD;
&#xD;
          -  Tipranavir.&#xD;
&#xD;
          -  Inability or unwillingness to comply with the requirements for the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayodeji Adegunsoye, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayodeji Adegunsoye, MD, MS</last_name>
    <phone>773-702-4844</phone>
    <email>deji@uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Spring Maleckar</last_name>
    <phone>773.834.4053</phone>
    <email>smaleckar@bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayodeji Adegunsoye, MD, MS</last_name>
      <phone>773-702-4844</phone>
      <email>aadegunsoye@medicine.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Spring Maleckar</last_name>
      <phone>773.834.4053</phone>
      <email>smaleckar@bsd.uchicago.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SECOVID</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Rapamune</keyword>
  <keyword>Post-COVID Fibrosis</keyword>
  <keyword>PASC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

